Last updated 11 January 2019

HPV vaccine safety surveillance data

From January 2018 a new HPV vaccine, Gardasil9®, is being funded under the National Immunisation Program. AusVaxSafety is monitoring the safety of HPV vaccine in 11- to 14-year olds. Injection site reactions, including pain, are known to occur following administration of HPV vaccines, and the current reported event rates are consistent with what are expected according to the existing data.

Maternal pertussis vaccine safety data

From 1 July 2018, maternal pertussis vaccine is being funded for pregnant women under the National Immunisation Program. AusVaxSafety is monitoring the safety of maternal pertussis vaccines in the days following immunisation. The current reported event rates are consistent with existing data on the safety of maternal pertussis vaccines.

Pertussis (whooping cough) vaccine safety data

Injection site reactions are known to occur following administration of acellular pertussis vaccines. The current reported event rates are consistent with existing data on pertussis vaccines.

Zoster (Shingles) vaccine safety data

In the context of no safety signals identified during two years of surveillance in over 18,000 participants, AusVaxSafety concluded active surveillance of zoster vaccine safety in November 2018. It is important to re-emphasise that zoster vaccine should not be given to immunocompromised individuals. For more information please refer to the Therapeutic Goods Administration (TGA) website.

Influenza vaccine safety data 

Surveillance of 2018 influenza vaccine safety commenced from 1 April 2018.
The current reported event rates are consistent with existing data on influenza vaccines.

Last updated January 2019